Literature DB >> 24722252

PRKAR1B mutation associated with a new neurodegenerative disorder with unique pathology.

Tsz Hang Wong1, Wang Zheng Chiu, Guido J Breedveld, Ka Wan Li, Annemieke J M H Verkerk, David Hondius, Renate K Hukema, Harro Seelaar, Petra Frick, Lies-Anne Severijnen, Gert-Jan Lammers, Joyce H G Lebbink, Sjoerd G van Duinen, Wouter Kamphorst, Annemieke J Rozemuller, E Bert Bakker, Manuela Neumann, Rob Willemsen, Vincenzo Bonifati, August B Smit, John van Swieten.   

Abstract

Pathological accumulation of intermediate filaments can be observed in neurodegenerative disorders, such as Alzheimer's disease, frontotemporal dementia and Parkinson's disease, and is also characteristic of neuronal intermediate filament inclusion disease. Intermediate filaments type IV include three neurofilament proteins (light, medium and heavy molecular weight neurofilament subunits) and α-internexin. The phosphorylation of intermediate filament proteins contributes to axonal growth, and is regulated by protein kinase A. Here we describe a family with a novel late-onset neurodegenerative disorder presenting with dementia and/or parkinsonism in 12 affected individuals. The disorder is characterized by a unique neuropathological phenotype displaying abundant neuronal inclusions by haematoxylin and eosin staining throughout the brain with immunoreactivity for intermediate filaments. Combining linkage analysis, exome sequencing and proteomics analysis, we identified a heterozygous c.149T>G (p.Leu50Arg) missense mutation in the gene encoding the protein kinase A type I-beta regulatory subunit (PRKAR1B). The pathogenicity of the mutation is supported by segregation in the family, absence in variant databases, and the specific accumulation of PRKAR1B in the inclusions in our cases associated with a specific biochemical pattern of PRKAR1B. Screening of PRKAR1B in 138 patients with Parkinson's disease and 56 patients with frontotemporal dementia did not identify additional novel pathogenic mutations. Our findings link a pathogenic PRKAR1B mutation to a novel hereditary neurodegenerative disorder and suggest an altered protein kinase A function through a reduced binding of the regulatory subunit to the A-kinase anchoring protein and the catalytic subunit of protein kinase A, which might result in subcellular dislocalization of the catalytic subunit and hyperphosphorylation of intermediate filaments.

Entities:  

Keywords:  PRKAR1B; intermediate filament; neurodegenerative disorders; neurofilament; protein kinase A

Mesh:

Substances:

Year:  2014        PMID: 24722252     DOI: 10.1093/brain/awu067

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  21 in total

1.  PRKAR1B mutations are a rare cause of FUS negative neuronal intermediate filament inclusion disease.

Authors:  Cyril Pottier; Matt Baker; Dennis W Dickson; Rosa Rademakers
Journal:  Brain       Date:  2014-11-20       Impact factor: 13.501

2.  Reply: PRKAR1B mutations are a rare cause of FUS negative neuronal intermediate filament inclusion disease.

Authors:  Tsz Hang Wong; Annemieke J M H Verkerk; Annemieke J Rozemuller; Rob Willemsen; Manuela Neumann; Vincenzo Bonifati; John van Swieten
Journal:  Brain       Date:  2014-11-19       Impact factor: 13.501

3.  A Novel PRKAR1B-BRAF Fusion in Gastrointestinal Stromal Tumor Guides Adjuvant Treatment Decision-Making During Pregnancy.

Authors:  Lindsey M Charo; Adam M Burgoyne; Paul T Fanta; Hitendra Patel; Juliann Chmielecki; Jason K Sicklick; Michael T McHale
Journal:  J Natl Compr Canc Netw       Date:  2018-03       Impact factor: 11.908

Review 4.  Parkinsonism, movement disorders and genetics in frontotemporal dementia.

Authors:  José Fidel Baizabal-Carvallo; Joseph Jankovic
Journal:  Nat Rev Neurol       Date:  2016-02-19       Impact factor: 42.937

Review 5.  Neurofilaments and Neurofilament Proteins in Health and Disease.

Authors:  Aidong Yuan; Mala V Rao; Ralph A Nixon
Journal:  Cold Spring Harb Perspect Biol       Date:  2017-04-03       Impact factor: 10.005

6.  Discovery of Allostery in PKA Signaling.

Authors:  Ping Zhang; Alexandr P Kornev; Jian Wu; Susan S Taylor
Journal:  Biophys Rev       Date:  2015-06-01

7.  Neurodevelopmental Impairment As the Main Phenotypic Hallmark Associated with the Translocation t(7;10)(7p22.3;q26.11).

Authors:  Mario Mastrangelo; Barbara Torres; Gloria De Vita; Marina Goldoni; Agnese De Giorgi; Laura Bernardini; Vincenzo Leuzzi
Journal:  J Pediatr Genet       Date:  2020-08-20

8.  Mutation frequency of PRKAR1B and the major familial dementia genes in a Dutch early onset dementia cohort.

Authors:  P E Cohn-Hokke; T H Wong; P Rizzu; G Breedveld; W M van der Flier; P Scheltens; F Baas; P Heutink; E J Meijers-Heijboer; J C van Swieten; Y A L Pijnenburg
Journal:  J Neurol       Date:  2014-08-10       Impact factor: 4.849

9.  Pure mechanistic analysis of additive neuroprotective effects between baicalin and jasminoidin in ischemic stroke mice.

Authors:  Peng-Qian Wang; Qiong Liu; Wen-Juan Xu; Ya-Nan Yu; Ying-Ying Zhang; Bing Li; Jun Liu; Zhong Wang
Journal:  Acta Pharmacol Sin       Date:  2018-01-18       Impact factor: 6.150

10.  Gpr161 anchoring of PKA consolidates GPCR and cAMP signaling.

Authors:  Verena A Bachmann; Johanna E Mayrhofer; Ronit Ilouz; Philipp Tschaikner; Philipp Raffeiner; Ruth Röck; Mathieu Courcelles; Federico Apelt; Tsan-Wen Lu; George S Baillie; Pierre Thibault; Pia Aanstad; Ulrich Stelzl; Susan S Taylor; Eduard Stefan
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-28       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.